Plant MicroRNAs - Novel Players in Natural Medicine? by Lukasik, Anna & Zielenkiewicz, Piotr
 International Journal of 
Molecular Sciences
Review
Plant MicroRNAs—Novel Players in
Natural Medicine?
Anna Lukasik 1 and Piotr Zielenkiewicz 1,2,*
1 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawinskiego 5a, 02-106 Warsaw,
Poland; alukasik@ibb.waw.pl
2 Department of Plant Molecular Biology, Institute of Experimental Plant Biology and Biotechnology,
University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland
* Correspondence: piotr@ibb.waw.pl; Tel.: +48-22-592-1108
Academic Editor: Andreas Keller
Received: 16 November 2016; Accepted: 16 December 2016; Published: 22 December 2016
Abstract: MicroRNAs (miRNAs) represent a class of small non-coding RNAs that act as efficient
gene expression regulators and thus play many important roles in living organisms. Due to their
involvement in several known human pathological and pathogenic states, miRNA molecules have
become an important issue in medicine and gained the attention of scientists from the pharmaceutical
industry. In recent few years, a growing number of studies have provided evidence that miRNAs
may be transferred from one species to another and regulate gene expression in the recipients’
cells. The most intriguing results revealed that stable miRNAs derived from food plants may enter
the mammals’ circulatory system and, after reaching the target, inhibit the production of specific
mammalian protein. Part of the scientific community has perceived this as an attractive hypothesis
that may provide a foundation for novel therapeutic approaches. In turn, others are convinced about
the “false positive” effect of performed experiments from which the mentioned results were achieved.
In this article, we review the recent literature that provides evidence (from both fronts) of dietary,
plant miRNA uptake and functionality in various consumers. Additionally, we discuss possible
miRNA transport mechanisms from plant food sources to human cells.
Keywords: microRNA (miRNA); plant; cross-kingdom; gene expression regulation; human; natural
medicine; diseases
1. Introduction
1.1. MicroRNA Function
MicroRNAs (miRNAs) are a class of small (18–24 nt), single-stranded molecules that are evolutionarily
conserved among many known species. These non-coding particles mediate posttranscriptional gene
expression through target mRNA translation inhibition or degradation by exonuclease action,
decapping, or deadenylation of the poly(A) tail [1–4]. It is estimated that more than 60% of human
protein-coding genes contain at least one conserved miRNA binding site and numerous non-conserved
sites [5]. Thus, it is not surprising that through their action, miRNAs control crucial biological processes,
such as developmental timing, apoptosis, metabolism, immune responses, hormone signaling, cell
proliferation, differentiation, and many others [6–9]. In plants, miRNAs also play roles in flowering,
polarity, nutrient homeostasis, phase change, biotic and abiotic stress responses [10,11].
Using the rapidly advancing experimental and computational methods, especially high-throughput
sequencing approaches, miRNA molecules have been found in a wide spectrum of organisms, ranging
from viruses to algae, plants and animals [12–15]. Recent reports have shown that miRNA-like
molecules are also present in some fungi [16,17]. Overall, to date more than 35,000 mature miRNAs
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from 223 species have been annotated in the miRBase database (release 21) [18]. Growing interest in
miRNAs and technical capabilities have enabled researchers to identify these intriguing molecules
not only in various tissues, cells and organs but also in different body fluids, e.g., serum [19–21],
plasma [19,22,23], urine [24–26], breast milk [27–29], saliva [30,31], tears [32], semen [33,34], and
others [32,35]. Contrary to traditional beliefs on extracellular RNA stability, circulating miRNAs
are shown to be resistant to RNase activity and highly stable in extreme pH and temperature
conditions [21,36–38]. More importantly, it has been reported that the profiles of miRNAs, especially in
serum, plasma and urine, are tightly correlated with various diseases and pathological states, including
cancer, diabetes, inflammation, infections and tissue injuries [20,24,39–44]. Thus, miRNA molecules
become new biomarkers to diagnose, prognosis, and monitor patients’ treatment responses [19,45–48].
Concerning the abundance of miRNAs in biological fluids, a very interesting aspect is miRNA
identification in breast milk. Breastfeeding is an essential process in infant health and development,
especially immune system development [49–51]. Several studies have shown that membranous vesicles,
called exosomes, that are present in human milk and colostrum are enriched in miRNAs [27,29,52,53].
miRNA “shipment” in mentioned carriers was proven to protect these molecules from harsh conditions
present in the human gastrointestinal (GI) tract. Thus, researchers have assumed that miRNAs may be
transferred to the bodies of infants via the GI tract and are likely to contribute to its development as well
as protection against infections [27,29,52]. miRNA molecules, namely those that are bovine-derived,
have been also identified in commercially available infant formula and various milk products [54–56].
The same as human molecules, the mentioned miRNAs from raw bovine milk were shown to be packed
in exosomes which protect them from degradation [57–60]. However, as reported by Howard et al.,
the pasteurization, homogenization and other processing of milk reduces miRNA concentrations [61].
Recent findings [62] suggest that certain bovine milk-derived miRNAs are bioavailable and appear
in adult human blood after consumption. Additionally, one of these miRNAs (miR-29) was shown
to regulate specific human gene expression [62]. This report was however questioned [63,64] by
other authors.
1.2. miRNAs in Therapy—Current Knowledge
Due to their involvement in various biological processes and thus in several human diseases,
miRNA molecules quickly became interesting to the pharmaceutical industry. Although drug discovery
has often been successful, developing new therapeutics is now becoming an increasingly expensive
business, in turn, a large number of disease-related proteins cannot be targeted or modulated by
a drug molecule. These “undruggable” proteins are not the only challenge facing the pharmaceutical
industry. Despite their confirmed efficacy, the available therapeutics for many known diseases still
present significant adverse effects. Therefore, in view of miRNA involvement in the regulation of gene
expression, it is not surprising that the attention of scientists from the pharmaceutical industry has
shifted to miRNA molecules. Currently, 23 years after the first report of the existence of miRNA [65,66],
several miRNA-related drugs are in clinical trials or are even close to reaching the market (e.g.,
Miravirsen and MRX34) [67–69]. These miRNA-based therapeutics comprise mainly two approaches:
(1) miRNA inhibition—synthetic single-stranded RNAs (called anti-miRs), which antagonize the
action of endogenous miRNA and lead to the upregulation of the specific protein population; and
(2) miRNA enhancement—synthetic miRNAs (called miRNA mimics), which are used to mimic
endogenous miRNAs and therefore achieve the same function by inhibiting the translation/mediating
the degradation of target mRNAs [67,68,70].
Although the previously described approaches may sound easy to introduce, in practice, their
development presents many challenges, mainly off-target effects, poor stability and inefficient delivery.
To overcome these barriers, several advanced strategies have been investigated and introduced;
for example, a variety of RNA chemical modifications can successfully enhance the stability of
the molecule and reduce off-target effects. The major types of chemical modifications used in
miRNA-related therapies include: (1) phosphorothioate (PS) backbone modification; (2) ribose 2′-OH
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group modifications (such as the 2′-O-methyl group, which is present natively in plant miRNAs);
and (3) locked (LNA) or unlocked (UNA) nucleic acids. Combinations of different modification
approaches are also very popular [68,71]. Although the mentioned modifications can improve the
stability and reduce off-target effects, the effective delivery of therapeutic miRNA molecules is still
challenging. Many therapies tested in clinical trials have used viral vectors to deliver RNA molecules,
e.g., adenoviruses, adeno-associated viruses and lentiviruses [68,72]. Because there are serious concerns
related to this strategy, such as immunogenicity or risk of insertional mutagenesis, the attention of
researchers has focused on nonviral vectors. Two recently intensively investigated categories of
delivery systems are: (1) lipid-based; and (2) polymer-based vectors, particularly polyethylenimine
(PEI)-based delivery systems, dendrimers, and poly(lactide-co-glycolide) (PLGA) particles. In addition
to synthetic materials, naturally occurring ones, such as chitosan, protamine and atelocollagen,
have been used for RNA delivery purposes [68,70,73]. Concerning natural transport vesicles, some
labs have shown that self-derived exosomes, as well as exosome-like nanoparticles derived from
grapefruit, grape and bovine milk, can serve as ideal cargo for drug delivery, including miRNA-based
therapeutics [74–77]. The delivery method with the use of self-derived or natural exosomes is very
appealing and promising; however, at the same time, nontrivial. It was shown that unmodified exosomes
administered systematically to the animal organism accumulate in the liver, are rapidly cleared by
renal system or deliver their cargo to unintended tissues [78,79]. The efficiency of exosomes targeting
specific tissues can be successfully enhanced by displaying homing peptides or ligands on the surface
of the exosomes that will target the recipient cell bearing cognate receptor [80–83]. Various targeting
peptides can have different affinity or can be cleaved/degraded, losing their target capability. Therefore,
mentioned modifications should be carefully selected to fully perform the desired function [84].
1.3. Cross-Kingdom Gene Expression Regulation by miRNAs
Growing interest in miRNA molecules since their discovery in 1993 led to the uncovering of
their ability to transfer and regulate gene expression in a cross-kingdom manner, namely, affecting
the organism from which they do not originate. To this day, the discussed field has primarily been
dominated by viruses, which, through their miRNA molecules, are able to not only enter the latent
phase, thus avoiding the host immune response, but also control specific processes in host cells and
facilitate the process of infection. There are several well-known examples of animal virus miRNA–host
interactions. One of them is the miR-BART5 molecule encoded by the Epstein-Barr virus (EBV), which
inhibits the production of the pro-apoptotic p53-upregulated modulator of apoptosis (PUMA) protein
and thus enables the infected cells to avoid elimination by apoptosis [85]. Recent studies have provided
evidence of the existence of miRNAs that exhibit anti-viral properties. The miR-32 molecule, which is
able to block the replication of the primate foamy virus type 1 (PFV-1) in humans, is an example [86].
In turn, the cytoplasmic miRNA cluster, consisting of miR-28, miR-125b, miR-150, miR-223 and
miR-382 molecules, interacts with human immunodeficiency 1 virus (HIV-1) in non-activated T CD4+
lymphocytes and inhibits its multiplication [87].
Interesting work concerning this topic was conducted by LaMonte et al., who showed that two
human miRNAs (miR-451 and let-7i) highly enriched in erythrocytes carrying a variant hemoglobin
allele (HbS) are able to translocate into the malaria parasite Plasmodium falciparum. Moreover, these
miRNAs can fuse to the parasite’s mRNA, inhibit its translation and eventually affect P. falciparum’s
biology and survival [88]. Because erythrocytes carrying the mentioned variant hemoglobin allele cause
sickle cell disease and are resistant to malaria infection, LaMonte et al. suggested that investigated
miRNA’s activity may represent a novel host defense strategy against this pathogen [88].
A different level of cross-kingdom gene expression regulation by miRNAs was presented by
Zhang et al. in an intriguing study in 2012. In their publication, the authors provide evidence that the
plant miRNA MIR168a from a food source, namely Oryza sativa (rice), is present and stable in human
serum [89]. Additionally, they showed that MIR168a targets the mRNA of the low-density lipoprotein
receptor adaptor protein 1 (LDLRAP1). This miRNA was able to reduce the LDLRAP1 protein level in
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the blood and liver of mice fed rice, which eventually resulted in an increase in low-density lipoproteins
(LDL) in their plasma [89]. Zhang et al. revealed also that more than half of the MIR168a in serum is
abundant in microvesicles (MV) and that the mentioned molecules can use the mammalian Argonaute
2 (AGO2) protein to form the RNA-induced silencing complex (RISC) and execute their functions.
The described work was the first to present evidence that plant miRNAs may pass the GI tract, enter
the circulation and, most importantly, function in a cross-kingdom manner.
Zhang et al.’s report [89] motivated many scientists to investigate this issue in more depth.
Some scientists successfully showed that plant, food-derived miRNAs may transfer to animals and
regulate gene expression in their cells. In turn, others presented contradicting evidence of plant miRNA
uptake and their influence on biological processes in animals. In this review, we summarize the current
knowledge concerning cross-kingdom regulation by plant-derived miRNAs and consider how these
molecules may transport from food to animal target cells. Finally, we briefly discuss how these findings
may impact medicine and nutrition.
2. Detection and Function of Plant miRNAs in Animals—Supporting Evidence
Following Zhang’s article, research performed by Wang et al. detected a high number of small
RNAs originating from various exogenous species, including dietary plants, in human plasma [90].
The most abundant miRNAs in the presented profile originated from Zea mays (corn) and Oryza sativa
(rice). In addition to these cereal grains, Wang et al. were able to identify RNA molecules from
other common food plant species, such as Solanum lycopersicum (tomato), Glycine max (soybean) and
Vitis vinifera (grapes). Consistent with Zhang’s et al. study, small RNAs detected in human plasma
were resistant to RNase A activity. Thus, the authors suggested that the investigated small RNA
(sRNA) molecules may be accompanied by certain proteins, lipids and other particles that protect
them from degradation [90].
In 2014, Liang et al. published the effects of a mouse feeding study in which animals received
total RNA extract from Brassica oleracea (cabbage) [91]. Their findings showed that the investigated
cabbage miR172 persisted through the GI tract for 72 h after feeding. Moreover, the authors were able
to detect the mentioned miRNA within 2 h after feeding in mouse blood and different organs, such as
the liver, spleen and kidney [91]. The next year, Hongwei Liang and coauthors published their results
of an experiment in which volunteers drank watermelon juice or ate fruit (watermelon, banana, apple,
orange, grape, mango and cantaloupe) [92]. Using quantitative reverse transcriptase PCR (qRT-PCR)
and Northern blot methods, they were able to identify 10 selected plant miRNAs in human plasma at
high basal levels [92].
The abundance of plant miRNAs in biological fluids was investigated by our team as well.
Based on the evidence that endogenous miRNAs are present in breast milk and may regulate
specific human gene expression [27,29,52], we decided to evaluate whether potentially food-derived
miRNA molecules can be found in the breast milk from mammalian species [93]. The restrictive
bioinformatics analysis of publicly available, raw data from high-throughput sequencing studies on
miRNA composition in human and porcine breast milk exosomes led to identification of several plant
miRNA species, e.g., MIR168a, MIR156a, MIR166a, MIR319b and MIR167d. Most of the identified
plant molecules belong to evolutionarily conserved MIR families [93]. It is also important to note that
the revealed plant miRNA profiles from mammalian breast milk were similar to the composition in
human blood presented by Zhang et al. [89].
Two separate studies carried out by Yang et al. [94,95] demonstrated that diet-derived small
RNAs are present in the sera and urine of plant-consuming animals. Their studies were focused on
MIR2911 from the Lonicera japonica (honeysuckle) herb. The MIR2911 molecule was shown to appear
in the circulation 3 days after starting the diet, and its level was associated with dietary intake levels.
After the end of feeding, miRNA remained in the examined fluids for 48 h [94]. Yang et al. showed
additionally that dietary MIR2911 in sera was not associated with the AGO2 protein and its uptake
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was not related to perturbations in gut permeability or the microbiome [95]. However, they proposed
that certain diet or GI injuries may facilitate the delivery of diet-derived sRNAs [94].
The previously discussed MIR2911 molecule has also become a topic of interest of Zhang’s group,
who published the initial study on cross-kingdom gene expression regulation by plant MIR168a [89].
In 2014, mentioned authors reported that drinking or eating a boiled honeysuckle decoction led to
the elevation of the MIR2911 level in the sera and lungs of mice [96]. Additionally, the luciferase
reporter assay and in vivo experiments showed that MIR2911 is able to target influenza A virus (IAV),
particularly H1N1, H5N1, and H7N9, and consequently inhibit its replication and reduce mouse
mortality. Intriguingly, honeysuckle has been known in traditional Chinese medicine for centuries
and is used to treat influenza infections. Another interesting observation that can be drawn from
the described study is that boiling of honeysuckle did not lead to the degradation of MIR2911 [96].
This is consistent with other research, which demonstrated that storage, processing and cooking do
not abolish plant miRNA in food sources and that plant-derived miRNAs can survive in a simulated
digestion system for at least 75 min [97]. The same authors of the above-described MIR2911 study went
a step further and recently published their results showing that plant food-derived sRNAs are present
in human umbilical blood and amniotic fluids [98]. Therefore, they proposed that miRNAs can pass
through the placenta and enter the fetus. Because most of the investigated MIR2911 molecules were
present in MVs after feeding, the transplacental sRNA transport was suggested to be mediated by these
carriers [98]. To further explore the properties of small RNAs that passed through the placenta, Li et al.
performed experiments revealing that after feeding, the synthetic small interfering RNA (siRNA) level
was significantly elevated in the mouse fetus, while the siRNA target alpha-fetoprotein (AFP) level
was downregulated [98].
The therapeutic potential of plant-based miRNAs was also recently confirmed by two different
groups. Using a colon cancer mouse model, one study reported that the oral administration of
a cocktail of three tumor suppressor miRNAs with methyl groups at the 2′ position of the 3′ nucleotide
(mimicking plant miRNAs) reduced the colon tumor burden [99]. The second study found that plant
miR159 is present in a woman’s sera and its level is inversely correlated with breast cancer morbidity
and progression [100]. Most of the identified miR159 was abundant in extracellular vesicles (EV).
More importantly, in vitro experiments performed by the mentioned group revealed that synthetic
miR159 is capable of reducing the proliferation of breast cancer cells by targeting sequence of the 3′
untranslated region (UTR) of Transcription Factor 7 (TCF7) mRNA. In turn, the oral administration of
miR159 mimic significantly inhibited the growth of xerograph breast tumors in mice [100].
3. Detection and Function of Plant miRNAs in Animals—Contradicting Evidence
Along with all of the presented research supporting the dietary uptake and cross-kingdom
function of plant miRNAs, a large amount of contradicting evidence was also published, including
criticisms of Zhang et al.’s study [101,102]. The possibility of batch effects, contamination or
technical variability resulting from RNA extraction, library preparation and sequencing was discussed.
Moreover, the strategy of pooling individual samples was also described. It has been suggested that
a minority of donors could be responsible for most of the plant pooled reads. In turn, the quantity of
raw rice given to mice in feeding experiments was high beyond the normal food intake level [101].
The stoichiometric and delivering considerations for plant–mammal sRNA communication were
critically discussed in a book chapter written by Kenneth W. Witwer entitled “Non-coding RNAs and
Inter-kingdom Communication” [103].
Correspondingly, several independent research groups have reported negative results of their
plant-based miRNAs feeding studies in a variety of insects and animals. Snow et al. found a substantial
level of plant MIR156a, MIR159a and MIR169a in a diet commonly consumed by humans, mice and
honeybees [104]. However, in the plasma of healthy athletes who routinely eat fruits (e.g., bananas,
apples and avocados), listed miRNAs could not be detected. Similar negative findings were shown for
honeybees, which received pollen, honey and nectar as a food source, and in mice on a vegetarian/soy
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or avocado diet [104]. To expand the honeybee feeding study, Snow et al. performed and published
further research in which they elucidated the level of plant miRNAs in different tissues of newly
eclosed, nurse and forager bees. Their results showed that honeybees are able to ingest high levels of
pollen-derived miRNAs; however, the systemic levels of these molecules are far below biologically
relevant concentrations [105].
An additional study performed by Witwer et al. also failed to detect plant-derived miRNAs in
animal plasma [106]. In their research, the authors measured plant uptake in two pigtail macaques
fed a soy- and fruit-based mixture. The levels of certain plant miRNAs in the blood were evaluated
before and after (1, 4 and 12 h) ingestion by qRT-PCR and droplet digital PCR. Although Witwer et al.
observed very low levels of some of the investigated molecules, these low levels were interpreted as
a result of non-specific amplification [106].
Recently, another research group aimed to detect plant miRNAs in the plasma of healthy
volunteers that usually consume extra virgin olive oil (EVOO) [107]. They evaluated the abundance
of plant miRNAs 2 h after the ingestion of EVOO using the high-throughput sequencing approach.
Similarly to the studies discussed above, the authors failed to identify plant miRNAs in the mentioned
body fluids. Micó et al. assumed that miRNAs present in plant-derived products, such as EVOO or
beer, could be absorbed by the human gut and enter the circulation. However, primarily, they did not
detect substantial quantities of plant miRNAs in the EVOO and beer samples [107].
The initial study by Zhang et al. [89] sparked also discussion on genetically modified organisms
(GMOs). Many web services and magazines started to publish articles and comments concerning
the unintended effect of miRNAs derived from consumed GMOs [108–112]. Despite the fact that
the study by Zhang et al. did not directly address GMOs, the situation became so “uncomfortable”
that scientists from the Monsanto corporation, the leading producer of genetically engineered seeds,
published (on-line) their technical analysis of the Zhang et al. study [113] and a review discussing
the safety of food from biotechnology-derived crops [114]. Moreover, together with researchers from
the miRagen company, they made an effort to replicate the initial Zhang et al. experiment [115].
In their study, mice received one of three dietary formulations: standard chow, a nutritionally sufficient
diet containing 41% rice or raw rice. Unfortunately, no or very little plant miRNA was detected in
the plasma and organs of animals fed any of these diets. In turn, the levels of LDL in the mouse
liver were increased, but the expression of the investigated LDLRAP1 protein remained unchanged
across all examined groups [115]. Researchers from the Monsanto corporation performed additionally
a survey of a large number of publically available sRNA datasets from animal fluids and tissues [116].
Their bioinformatics analyses revealed that of the 83 RNA datasets examined, 63 had at least one
sequence representing plant miRNA. The most abundant molecule was MIR168, with a sequence
typical of monocot plant species. The mentioned miRNA was also found in datasets for insects that did
not feed on monocot plants, complemented by sequencing data from the scientist’s own insect feeding
experiment. Based on the mentioned survey, the researchers from the Monsanto corporation assumed
that the plant miRNAs observed in animal datasets may originate in the process of sequencing [116].
4. miRNA Transport from Cell to Cell
Beyond competing arguments on whether the cross-kingdom regulation of gene expression by
plant miRNAs (abundant even in low amounts) is possible, questions concerning how these molecules
can pass through the GI tract, enter the circulation and transport from cell to cell have also been
raised. In recent years, several intracellular carriers of endogenously originating miRNAs have been
identified, including microvesicle (MV) compartments, which are membrane-derived vesicles released
from various types of cells [117–120]. Based on their origin, size and mechanism of formulation, they
can be divided into: (1) shedding vesicles (SVs), which directly bud from the cell surface; (2) exosomes,
which are derived from the endosomal membrane; and (3) apoptotic bodies, which are released
in response to apoptotic stimuli [121–123]. Listed vesicles were shown to protect miRNAs from
degradation by RNases [117,124–126]. In some plants, exosome-like nanoparticles (called EPDENs)
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have been identified and were shown to carry proteins, lipids, and miRNAs [76,77,127,128]. One of
the published studies suggested that EPDENs may mediate interspecies communication and induce
the expression of certain human genes [128]. Extracellular miRNAs can be alternatively transported by
lipoproteins, namely high-density lipoproteins (HDL) and low-density lipoproteins (LDL) [129,130].
As the main functional component of the microRNA ribonucleoprotein complex (miRNP), the AGO
protein has also been observed to carry miRNA molecules [37,131].
Another issue is related to the passage of plant miRNAs through the GI tract. One option is
that the intestinal epithelial cells take up miRNAs from food. In Caenorhabditis elegans, a ubiquitously
expressed transmembrane systemic RNA interference defective protein 1 (SID-1) was shown to mediate
the passive cellular uptake of double stranded RNAs (dsRNAs) [132,133]. In turn, the SID-2 protein
localized in the intestine luminal membrane was thought to mediate the endocytosis of dsRNAs
from the lumen [134]. Two homologous proteins of SID-1, SID1 transmembrane family member 1
(SIDT1) and SID1 transmembrane family member 2 (SIDT2), were also identified in most vertebrates.
Their exact biochemical properties are still under investigation. However, previous reports have
suggested that mentioned proteins may have similar functions to those present in C. elegans. Namely,
human SIDT1 in pancreatic cells was shown to enhance siRNA uptake while in embryonic kidney
cells, to mediate the intracellular transport of small RNAs [135–137]. Although many gaps in the body
of knowledge on miRNA transport need to be filled, it can be assumed that the miRNA pathway
from plant food sources to recipient cells may be as follows: by consuming plant material, we crush
it mechanistically by oral activity and partially digest it by various enzymes in our mouth/stomach.
During these processes, plant miRNAs are released from destroyed cells and transferred to the small
intestine. After being incorporated into certain proteins or vesicles, they are secreted and transported
to the target cells via the circulatory system.
5. Conclusions
Despite their small size, miRNA molecules possess huge potential due to their ability to regulate
target gene expression. miRNA profiles have been shown to correlate with many human diseases
and pathological stages, which makes them even more attractive for scientists and the pharmaceutical
industry. The ability of miRNAs to regulate gene expression in a cross-kingdom manner was already
shown for viruses and parasites, whereas Zhang et al. were the first to demonstrate these intriguing
properties for plant molecules [89]. Their study launched a wave of publications competing in
arguments and started fierce debate among scientists that continues to this day. Table 1 summarizes
all the arguments presented in this review. The results of Zhang et al. [89] came also as an attractive
hypothesis that may reveal the molecular mechanism of certain folk remedies. The plant kingdom
is full of species that have been used for their medical properties since the dawn of history. So far,
some of these properties are associated with minerals, vitamins, antioxidants, proteins or other small
molecules, whereas mechanisms regarding rest of them remain unknown. Therefore, in light of the
presented studies, miRNAs may be another component responsible for the medical properties of plants.
Considering this in a boarder sense, the well-known Hippocrates quote “Let food be thy medicine
and medicine be thy food” may gain a new meaning. Without a doubt, the cross-kingdom transfer
of plant miRNAs and their therapeutic potential need to be further investigated and unambiguously
confirmed. Any potential risk should also be seriously considered. This process will facilitate the
development of new approaches to prevent or treat several known human diseases.
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Table 1. Summary of arguments for and against the theory of cross-kingdom communication by plant microRNAs (miRNAs) presented by recent studies.
Evidence Results Methods Used References
Supporting Evidence
MicroRNA MIR168 molecules from Oryza sativa (rice) were abundant in human serum.
MIR168 were present in microvesicles (MV) and could associate with the human Argonaute 2 (AGO2).
MIR168 negatively regulated the expression of the human low-density lipoprotein receptor adaptor
protein 1 (LDLRAP1) protein in liver, which in turn resulted in low-density lipoprotein (LDL) increase
in plasma.
• High-throughput sequencing,
• Quantitative reverse transcriptase PCR
(qRT-PCR) and semi-quantitative RT-PCR,
• Northern blot,
• Bioinformatics analysis,
• Luciferase reporter assay,
• Western blot,
• AGO2 immunoprecipitation.
[89]
Certain plant miRNAs were present in human plasma and may be associated with some particles
protecting them from degradation. High-throughput sequencing [90]
MIR172 from Brassica oleracea (cabbage) was present in mouse serum and various tissues after animal
feeding with plant extract.
• Electrophoresis,
• RT-PCR. [91]
Ten selected plant miRNAs were present in the plasma of volunteers drinking watermelon juice or
eating different fruits.
Plant miRNAs were largely encapsulated in MV.
• qRT-PCR,
• Northern blot. [92]
Several plant miRNAs were identified in exosomes isolated from mammalian breast milk. Bioinformatics analysis [93]
MIR2911 and MIR168 from Lonicera japonica (honeysuckle) were found in the sera and urine of mice
fed a plant-based diet.
The level of a molecule was associated with the dietary intake level.
Specific diet or/and alterations in intestinal permeability may improve plant miRNA absorption.
• qRT-PCR and digital droplet PCR,
• AGO2 immunoprecipitation,
• Fluorometry.
[94,95]
MIR2911 from Lonicera japonica (honeysuckle) was found in the sera and lungs of mice fed
a honeysuckle decoction.
MIR2911 directly targeted Influenza A virus and inhibited its replication.
• Luciferase reporter assay,
• Bioinformatics analysis,
• High-throughput sequencing,
• qRT-PCR,
• Northern blot,
• Ago2 immunoprecipitation,
• Western blot.
[96]
Plant miRNAs were stable in a simulated human digestion system for over 1 h.
Plant miRNAs could survive storing, cooking and other types of processing.
• Drug dissolution tester,
• qRT-PCR. [97]
Plant miRNA was found in human umbilical cord blood and amniotic fluids.
MIR2911 from Lonicera japonica (honeysuckle) could transfer through the placenta and enter fetal liver
in mice.
MIR2911 was primarily present in MV.
• qRT-PCR,
• High-throughput sequencing,
• Confocal microscopy analysis.
[98]
Cocktail of 3 miRNA mimicking small RNAs produced in plants reduced colon cancer. • Periodate oxidation and qRT-PCR,• Dissecting microscope. [99]
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Table 1. Cont.
Evidence Results Methods Used References
Plant MIR159 was present in a woman’s sera.
Oral administration of synthetic MIR159 suppressed the growth of breast tumors in mice.
MIR159 was predominantly present in extracellular vesicles (EV).
• Sodium periodate qPCR and qRT-PCR,
• High-throughput sequencing,
• Bioinformatics analysis,
• RISCTRAP assay,
• Dual-luciferase reporter assay,
• In situ hybridization,
• Immunohistochemistry,
• Western blot.
[100]
Contradicting Evidence
Critical discussions on plant-mammal sRNA communication (including the study by
Zhang et al.)—issues:
• Contamination,
• Batch effects,
• Technical variability,
• Stability of plant miRNAs in mammalian organisms,
• Transport of plant miRNAs to mammalian cells,
• Functionality of plant miRNAs,
• Stoichiometry,
• Safety of biotech-derived food.
• Not experimental—discussion based on
current knowledge/previous studies,
• Bioinformatics re-analysis of the study by
Zhang et al.
[101–103,113,114]
Plant miRNAs could not be detected in the plasma of healthy athletes consuming fruits.
Plant miRNAs were undetectable in the plasma and tissues of mice on a vegetarian diet.
Plant miRNAs were undetectable in tissues of newly eclosed, nurse and forager honeybees fed with
pollen/honey/nectar, or their systemic level was below relevant, active concentrations.
qRT-PCR [104,105]
Plant miRNAs were not present in blood obtained before and after feeding of pigtailed macaques with
a miRNA-rich plant-based substance. qRT-PCR and droplet digital PCR [106]
Plant miRNAs could not be detected in the plasma of volunteers consuming extra virgin olive oil. High-throughput sequencing [107]
None or very few plant miRNAs were found in the liver and plasma of mice fed any of the described
diet regimens.
The LDL level in mouse plasma was increased; however, this was proposed as a result of the
short-term nutritional impact of the rice diet following the fasting period.
The LDLRAP1 protein level was not reduced in the mouse liver.
• High-throughput sequencing,
• qPCR,
• Enzyme-linked immunosorbent assay
(ELISA).
[115]
Plant miRNAs were observed in public animal sRNA datasets and sequencing data from insect
feeding experiments.
Identified plant miRNAs may be an artifact of the sequencing methodology.
• High-throughput sequencing,
• Bioinformatics analysis,
• Northern blot.
[116]
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